CN Patent

CN102958528A — 取代β-环糊精稳定的泊沙康唑静脉输注液制剂

Assigned to Merck Sharp and Dohme LLC · Expires 2013-03-06 · 13y expired

What this patent protects

本发明涉及用作用于静脉内给药的泊沙康唑的药物组合物的水溶液。所述组合物包括增溶剂，如酸化溶液中的改性β-环糊精，其还可以包括螯合剂，如依地酸二钠（EDTA）。在临床试验中，发现200mg泊沙康唑剂量的所选组合物能够达到可接受的药代动力学性质。

USPTO Abstract

本发明涉及用作用于静脉内给药的泊沙康唑的药物组合物的水溶液。所述组合物包括增溶剂，如酸化溶液中的改性β-环糊精，其还可以包括螯合剂，如依地酸二钠（EDTA）。在临床试验中，发现200mg泊沙康唑剂量的所选组合物能够达到可接受的药代动力学性质。

Drugs covered by this patent

Patent Metadata

Patent number
CN102958528A
Jurisdiction
CN
Classification
—
Expires
2013-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.